Clinical Trials Browser

Phase 1/2 × Lethal Congenital Contracture Syndrome 2 × 90 days × Clear all

NCT07070232 2026-03-12

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Phase 1/2 Recruiting

DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms